Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study

Journal of Clinical Psychopharmacology

Volumn 29, Issue 3, 2009, Pages 239-247

  Adler, Lenard A ^a,b   Zimmerman, Brenda ^c   Starr, H Lynn ^d   Silber, Steve ^e   Palumbo, Joseph ^e   Orman, Camille ^e   Spencer, Thomas ^f,g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c McNeil Laboratories Inc   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adult ADHD; Concerta; OROS methylphenidate; Stimulant

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ABNORMAL THINKING; ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; BRUXISM; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LABORATORY TEST; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MUSCLE TIGHTNESS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TOOTH PAIN; VITAL SIGN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METHYLPHENIDATE; MIDDLE AGED; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649255981     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181a390ce     Document Type: Article

References (48)

1. Wilens TE, Faraone SV, Biederman J. Attention deficit/hyperactivity disorder in adults. JAMA. 2004;292:619-623.
2. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237-248.
3. Faraone SV, Biederman J, Spencer T, et al. Attention-deficit/ hyperactivity disorder in adults: an overview. Biol Psychiatry. 2000;48:9-20.
4. Turner DC, Blackwell AD, Dowson JH, et al. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2005;178:286-295.
5. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524-540.
6. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792-1798.
7. Murphy K, Barkley R. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord. 1996;1:147-161.
8. Barkley RA, Murphy KR, Dupaul GI, et al. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002;8:655-672.
9. Biederman J, Fried R, Monuteaux MC, et al. A laboratory driving simulation for assessment of driving behavior in adults with ADHD: a controlled study. Ann Gen Psychiatry. 2007;6:4.
10. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
11. Faraone SV, Spencer TJ, Montano CB, et al. Attention-deficit/ hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164:1221-1226.
12. Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006;163:1720-1729.
13. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161:1948-1956.
14. Davidson MA. ADHD in adults: a review of the literature. J Atten Disord. 2008;11:628-641.
15. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008;65:835-842.
16. Pliszka S, and the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
17. Greenhill LL, Pliszka S, Dulcan MK; American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:25S-49S.
18. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434-443.
19. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:456-463.
20. Biederman J, Mick E, Spencer T, et al. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006;11:390-396.
21. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59:829-835.
22. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63:981-989.
23. Kooij JJ, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med. 2004;34:973-982.
24. Fallu A, Richard C, Prinzo R, et al. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin. 2006;22:2557-2566.
25. Spencer TJ, Adler LA, McGough JJ, et al; Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61:1380-1387.
26. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007;68:93-101.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC: American Psychiatric Press; 2000.
28. Adler LA, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:187-201.
29. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
31. Spencer TJ, Adler L. Diagnostic approaches to adult ADHD. Prim Psychiatry. 2004;11:49-53.
32. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775-782.
33. National Institute of Mental Health. CGI (Clinical Global Impression) scale. Psychopharmacol Bull. 1985;21:839-843.
34. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258-266.
35. Adler LA, Spencer T, Faraone SV, et al. Training raters to assess adult ADHD: reliability of ratings. J Atten Disord. 2005;8:121-126.
36. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:E105.
37. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60:204-211.
38. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:883-892.
39. Gau SS, Shen HY, Soong WT, et al. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol. 2006;16:441-455.
40. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13:e50-e62.
41. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44:1015-1023.
42. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112:e404.
43. Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. 2005;22:498-512.
44. Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc. 2005;97:11S-16S.
45. Wigal SB, Wilens TE, Wolraich M, et al. Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention-deficit/hyperactivity disorder: 2-year, open-label study results. Pediatrics. 2007;120:e120-e128.
46. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160:82-90.
47. Cox DJ, Merkel RL, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118:e704-e710.
48. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11:625-639.